Elbit Imaging Ltd. Announces InSightec's ExAblate Neuro System Awarded European CE Mark for Non-invasive Treatment of

    Elbit Imaging Ltd. Announces InSightec's ExAblate Neuro System Awarded
 European CE Mark for Non-invasive Treatment of Neurological Disorders in the

PR Newswire

TEL AVIV, Israel, December 4, 2012

TEL AVIV, Israel, December 4, 2012 /PRNewswire/ --

Elbit Imaging Ltd. ("EI" or the "Company") (TASE, NASDAQ: EMITF) announced
today that on December 3, 2012, Elbit Medical Technologies Ltd. ("Elbit
Medical") (TASE: EMTC-M) (in which the Company holds approximately 90%),
announced that InSightec Ltd. ("InSightec") (in which Elbit Medical holds
approximately 64%, and 52.15% on a fully diluted basis) has been awarded the
European CE mark for its transcranial focused ultrasound system, ExAblate
Neuro, with respect to the treatment of neurological disorders in the brain,
including essential tremor, Parkinson's disease and neuropathic pain.

Treatment options for patients suffering from neurological disorders, who do
not respond to drug treatments include deep brain stimulation, radiofrequency
ablation and radiosurgery, which are invasive or involve ionizing radiation
and are associated with recognized radiation risks and high risk of
complications and side effects. As opposed to the above, InSightec elaborated,
ExAblate® Neuro offers a non-invasive treatment with no ionizing radiation by
treating tissue deep in the brain through an intact skull. MR guided Focused
ultrasound (MRgFUS) combines therapeutic acoustic ultrasound waves with
continuous MRI guidance. The MRI enables physicians to visualize, plan,
guide, monitor and control the treatment, while the ultrasound acoustic energy
destroys the targeted tissue in the brain. InSightec recently received its
second ExAblate FDA approval for the treatment of painful bone metastases in
patients who are unable or unwilling to undergo radiation. This is in addition
to FDA approval for uterine fibroids received in 2004.

About InSightec

InSightec Ltd. is privately held by Elbit Imaging, General Electric, and
MediTech Advisors. Founded in 1999, InSightec developed ExAblate to transform
MRI-guided Focused Ultrasound (MRgFUS) into a clinically viable technology.
ExAblate has won several awards for innovation and its potential to help
mankind, including The Wall Street Journal Technology Innovation Awards and
the European Union's IST grand prize. TIME magazine recently named Focused
Ultrasound as "one of 50 best inventions". For more information about
treatment centers and bone metastases please visit: http://www.insightec.com.

About Elbit Imaging Ltd.

Elbit Imaging Ltd. operates in the following principal fields of business: (i)
Commercial and Entertainment Centers - Initiation, construction and sale of
shopping and entertainment centers and other mixed-use real property projects,
predominantly in the retail sector, located in Central and Eastern Europe and
in India, primarily through its subsidiary Plaza Centers N.V. In certain
circumstances and depending on market conditions, we operate and manage
commercial and entertainment centers prior to their sale; (ii) U.S. Real
Property - Investment in commercial real property in the United States; (iii)
Hotels - Hotel operation and management; (iv) Medical Industries - (a)
research and development, production and marketing of magnetic resonance
imaging guided focused ultrasound treatment equipment and (b) development of
stem cell population expansion technologies and stem cell therapy products for
transplantation and regenerative medicine; (v) Residential Projects -
Initiation, construction and sale of residential projects and other mixed-use
real property projects, predominately residential, located primarily in India;
(vi) Fashion Apparel - Distribution and marketing of fashion apparel and
accessories in Israel; and (vii) Other Activity -venture capital investments.

Any forward-looking statements in our releasesinclude statements regarding
the intent, belief or currentexpectations of Elbit Imaging Ltd. and our
management about our business, financial condition, results of operations, and
its relationship with its employees and the condition of our properties. Words
such as"believe," "expect," "intend," "estimate" and similar expressionsare
intended to identify forward-looking statements but are not the exclusive
means of identifying such statements. Actual results may differ materially
from those projected, expressed or implied in the forward-looking statements
as a result of various factors including, without limitation, the factors set
forth in our filings with the Securities and Exchange Commission including,
without limitation, Item 3.D of our annual report on Form 20-F for the fiscal
year ended December 31, 2011, under the caption "Risk Factors." Any
forward-looking statements contained in our releases speak only as of the date
of such release, and we cautionexisting and prospectiveinvestors not to
place undue reliance on such statements. Such forward-looking statements do
not purport to be predictions of future events or circumstances, and
therefore, there can be no assurance that any forward-looking statement
contained our releases will prove to be accurate. We undertake no obligation
to update or revise any forward-looking statements.

For Further Information:

Company Contact:
Shimon Yitzhaki
Chairman of the Board of Directors
Tel: +972-3-608-6048

Investor Contact:
Mor Dagan
Investor Relations
Tel: +972-3-516-7620

SOURCE Elbit Imaging Ltd.
Press spacebar to pause and continue. Press esc to stop.